China's surging pharmaceutical research and development pipeline is pushing laboratory monkey prices back to Covid-19 pandemic-era highs, with suppliers quoting roughly 180,000 yuan (US$27,000) per animal — a level that is forcing some research teams to suspend studies entirely.

Supply squeeze tightens across research labs

The shortage is not merely a pricing problem, according to Guo Xiangyu, a scientist at Jinan University in Guangzhou who leads non-human primate model development at the Guangdong Provincial Key Laboratory of Non-Human Primate Research. Prices have climbed steadily since Chinese New Year, and availability has become an equally acute constraint. 'It is not just a question of price,' Guo said. 'In many cases, the monkeys simply cannot be bought. Suppliers say they have all been pre-booked.'

Guo's laboratory alone requires between 30 and 50 monkeys each year for work spanning pathological and molecular biological analyses. With pre-bookings absorbing available stock, researchers at institutions across China are reportedly facing similar bottlenecks.

Why it matters: drug R&D boom meets finite supply

Non-human primates — particularly macaques bred in provinces such as Guangdong, Guangxi, Yunnan, and Sichuan — are irreplaceable at late preclinical stages for neurological, oncological, and immunological drug candidates. China's accelerating new-drug approval pipeline, overseen by the National Medical Products Administration, has intensified domestic demand at a time when global pharmaceutical companies, including multinationals such as Merck and Bristol Myers Squibb, also rely on Chinese breeding facilities.

The pricing surge echoes conditions seen during the Covid-19 pandemic, when vaccine and antiviral research created a parallel demand shock. Industry observers and media outlets including Red Star News and Yicai have flagged the resurgence as a structural concern rather than a temporary blip.

The competitive backdrop

China has spent years building one of the world's largest non-human primate breeding industries, partly to reduce dependence on imports and to serve both domestic biotech and foreign contract research organisations. That infrastructure, concentrated heavily in Southeast Asia-adjacent southern provinces, is now struggling to keep pace with domestic pharmaceutical ambitions. Breeding cycles for macaques span several years, meaning supply cannot respond quickly to demand spikes.

The bottleneck also arrives as Western nations have tightened restrictions on primate imports from several source countries, effectively funnelling more global demand toward China-based suppliers and compounding the scarcity.

What's next

Researchers are reportedly exploring alternatives including organoids and advanced in-vitro models, but regulatory frameworks for novel drug approval still mandate primate data for many therapeutic categories. Until breeding capacity expands or regulators accept substitute models more broadly, labs with smaller procurement budgets face the starkest trade-offs. The trajectory of China's new-drug R&D pipeline — and how quickly breeders in Yunnan, Guangxi, and Sichuan can scale — will determine whether this supply crunch deepens through the remainder of 2026.